| Home > Publications Database > Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer. |
| Journal Article | DZNE-2023-00494 |
; ; ; ; ; ; ; ; ; ;
2023
National Acad. of Sciences
Washington, DC
This record in other databases:
Please use a persistent id in citations: doi:10.1073/pnas.2213140120
Abstract: Activation of heterotrimeric G-proteins (Gαβγ) by G-protein-coupled receptors (GPCRs) is a quintessential mechanism of cell signaling widely targeted by clinically approved drugs. However, it has become evident that heterotrimeric G-proteins can also be activated via GPCR-independent mechanisms that remain untapped as pharmacological targets. GIV/Girdin has emerged as a prototypical non-GPCR activator of G proteins that promotes cancer metastasis. Here, we introduce IGGi-11, a first-in-class small-molecule inhibitor of noncanonical activation of heterotrimeric G-protein signaling. IGGi-11 binding to G-protein α-subunits (Gαi) specifically disrupted their engagement with GIV/Girdin, thereby blocking noncanonical G-protein signaling in tumor cells and inhibiting proinvasive traits of metastatic cancer cells. In contrast, IGGi-11 did not interfere with canonical G-protein signaling mechanisms triggered by GPCRs. By revealing that small molecules can selectively disable noncanonical mechanisms of G-protein activation dysregulated in disease, these findings warrant the exploration of therapeutic modalities in G-protein signaling that go beyond targeting GPCRs.
Keyword(s): Vesicular Transport Proteins: metabolism (MeSH) ; Microfilament Proteins: metabolism (MeSH) ; Signal Transduction (MeSH) ; Receptors, G-Protein-Coupled: metabolism (MeSH) ; Heterotrimeric GTP-Binding Proteins: metabolism (MeSH) ; Neoplasms: metabolism (MeSH) ; G protein ; GPCR ; cancer ; drug discovery ; Vesicular Transport Proteins ; Microfilament Proteins ; Receptors, G-Protein-Coupled ; Heterotrimeric GTP-Binding Proteins
|
The record appears in these collections: |